Disertori M, Latini R, Maggioni AP, Delise P, Di Pasquale G, Franzosi MG, Staszewsky L, Tognoni G

Rationale and design of the GISSI-Atrial fibrillation trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence

J Cardiovasc Med 2006;7:29–38

Atrial fibrillation

To assess whether the addition of valsartan to best recommended therapy can reduce atrial fibrillation recurrence in patients with a recent history of atrial fibrillation and underlying cardiovascular disease or comorbidities

Randomised, double-blind, placebo-controlled

Aim 12 months

Aim 1402 patients, aged ≥ 40 years, with a recent episode of atrial fibrillation

Valsartan, 80 mg/day, titrated to 320 mg/day, or placebo

Prescribed treatments for atrial fibrillation including ACE inhibitors, amiodarone and beta-blockers at the discretion of the physician

Not yet available